BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
VANCOUVER, BC, and MADISON, Wis. , April 10, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac-for-Wildlife, Inc. ("SpayVac") jointly announce that SpayVac has partnered with a world leader in the aquaculture space to field test single-injection, long-lasting immuno-contraceptive vaccines in farmed rainbow trout.
不列顛哥倫比亞省溫哥華和威斯康星州麥迪遜，2024年4月10日 /PRNewswire/ — BioVaxys Technology Corp.（CSE：BIOV）（FRA：5LB）（OTCQB：BVAXF）（“BioVaxys”）（“BioVaxys”）和 SpayVac-for-Wildlife, Inc.（“SpayVax”）共同宣佈，SpayVac已與水產養殖領域的全球領導者合作進行單次注射實地測試，用於養殖虹鱒的長效免疫避孕疫苗。
SpayVac utilizes a patented liposome-based antigen delivery platform technology licensed from BioVaxys ( and has demonstrated a robust and sustained immune response in several species.
SpayVac採用了BioVaxys許可的基於脂質體的抗原遞送平台專利技術（並已在多個物種中顯示出強大而持續的免疫反應。
Large-scale contraception or sterilization plays a major role in the commercial aquaculture industry. As female fish mature, they put the majority of their energy into egg production, instead of muscle growth, which reduces the potential weight gain. Additionally, farm-raised fish that escape may breed with their wild counterparts and produce offspring that are less suited to surviving in the wild. Growing reproductively contracepted or sterile fish is the most effective way to manage these challenges.
大規模避孕或絕育在商業水產養殖業中起着重要作用。隨着雌魚的成熟，它們將大部分能量用於產卵，而不是肌肉生長，這會減少潛在的體重增加。此外，逃跑的農場養殖的魚類可能會與野生魚類一起繁殖，併產生不太適合在野外生存的後代。種植生殖避孕或不育魚類是應對這些挑戰的最有效方法。
Initial research field trials were started this spring in the Pacific Northwest. "We've been focused on developing vaccines to help manage free-ranging populations of animals like horses and deer, so this is an exciting new venture for us", said Dr. Bechert, Vice President of Research and Development for SpayVac-for-Wildlife, Inc.
初步的研究實地試驗於今年春天在太平洋西北地區開始。Spayvac-for-Wildlife, Inc.研發副總裁Bechert博士說：“我們一直專注於開發疫苗，以幫助管理馬和鹿等自由放養的動物種群，因此這對我們來說是一項令人興奮的新事業。”
In addition to fish aquaculture, SpayVac is planning to soon commercialize humane fertility control vaccines for deer, horses and other animals that are also based on the patented liposome-based delivery platform technology licensed from BioVaxys.
除了魚類水產養殖外，SpayVac計劃很快將針對鹿、馬和其他動物的人道生育控制疫苗商業化，這些疫苗也基於BioVaxys許可的基於脂質體的專利輸送平台技術。
James Passin, BioVaxys CEO, stated, "We are excited at the recent progress of our licensee, SpayVac-for-Wildlife, Inc., in advancing its fish immunocontraception research. The global market for farmed fish is estimated to exceed $306,000,000,0001. We look forward to continuing to support the important work of our partner SpayVac in the field of animal fertility vaccines."
BioVaxys首席執行官詹姆斯·帕辛表示：“我們對我們的被許可方SpayVac-for-Wildlife, Inc.最近在推進魚類免疫避孕研究方面取得的進展感到興奮。據估計，全球養殖魚類市場超過3.06億美元1。我們期待繼續支持我們的合作伙伴SpayVac在動物生育疫苗領域的重要工作。”
1 EMR Claight, Global Fish Farming Market Size, Share, Trends, Forecast 2023, 2024
1 EMR Claight， 2023、2024年全球魚類養殖市場規模、份額、趨勢、預測
About SpayVac-for-Wildlife, Inc.
關於 Spayvac-for-Wildlife, Inc.
SpayVac-for-Wildlife, Inc., ( based in Madison, Wisconsin, develops humane fertility-control vaccines for animals. SpayVac contraceptive vaccines are effective in a variety of species for multiple years with just a single injection. For questions about this research or SpayVac in general, please email [email protected].
Spayvac-for-Wildlife, Inc.（總部位於威斯康星州麥迪遜）爲動物開發人性化生育控制疫苗。SpayVac 避孕疫苗只需注射一次即可對多種物種有效多年。如對這項研究或一般的SpayVac有任何疑問，請發送電子郵件至 [email protected]。
About BioVaxys Technology Corp.
關於 BioVaxys 科技公司
BioVaxys Technology Corp. (), a biopharmaceutical company registered in British Columbia, Canada, is a clinical-stage company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and it's HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S, a DPX-based vaccine which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, DPX-RSV for Respiratory Syncytial Virus, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.
BioVaxys Technology Corp. () 是一家在加拿大不列顛哥倫比亞省註冊的生物製藥公司，是一家臨床階段的公司，致力於通過基於DPX免疫教育技術平台及其Haptenix “新抗原” 腫瘤細胞構建平台的新型免疫療法改善患者生活，用於治療癌症、傳染病、抗原脫敏和其他免疫學領域。該公司的臨床階段產品線包括基於DPX的疫苗MaveropePimut-S，目前正處於晚期復發難治性瀰漫性大B細胞淋巴瘤（DLBCL）和耐鉑卵巢癌的二期臨床開發、用於呼吸道合胞病毒的DPX-RSV以及使用其專有的 Haptenix “新抗原” 腫瘤細胞構建平台的個性化免疫治療疫苗 BVX-0918 即將進入西班牙治療屈光晚期卵巢癌的第一階段。該公司還利用其腫瘤免疫學專業知識，利用其個性化免疫治療疫苗創建了獨特的T淋巴細胞和其他數據集庫，以利用預測算法和其他技術來識別新的可靶向腫瘤抗原。
BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
BioVaxys的普通股在CSE上市，股票代碼爲 “BIOV”，並在法蘭克福證券交易所（FRA：5LB）和美國（場外交易代碼：BVAXF）上市。
ON BEHALF OF THE BOARD
代表董事會
Signed "James Passin"
James Passin, CEO
BioVaxys Technology Corp.
+1 646 452 7054
簽名 “詹姆斯·帕森”
首席執行官詹姆斯·帕森
BioVaxys 科技公司
+1 646 452 7054
ON BEHALF OF THE BOARD
代表董事會
Signed "Dr. Ursula Bechert"
Dr. Ursula Bechert
SpayVac-for-Wildlife, Inc.
+1 877 510 6812
簽名 “厄休拉·貝歇特博士”
厄休拉·貝切特博士
Spayvac-for-Wildlife, Inc.
+1 877 510 6812
Logo -
徽標-
SOURCE BioVaxys Technology Corporation
來源 bioVaxys 科技公司
譯文內容由第三人軟體翻譯。